Deborah Tanner - West Pharmaceutical Independent Director
| WST Stock | USD 319.79 3.20 1.01% |
Director
Ms. Deborah L. V. Keller Tanner is an Independent Director of the West Pharmaceutical Services, Inc. Ms. Keller serves as a Principal at Black Frame Advisors, LLC, having recently retired as Chief Executive Officer of Covance Drug Developmenta business segment of Laboratory Corporation of America Holdings. Prior to serving as CEO, Ms. Keller spent more than 28 years at Covance in a number of leadership roles, including Corporationrationrate Executive Vice President and Group President of Research and Development Laboratories, Corporationrationrate Senior Vice President and President of Discovery and Translational Services, and Vice President of Analytical Services in Europe. She is a trustee of the Wisconsin Alumni Research Foundation and serves on the Dean Advisory Board for the University of Wisconsin School of Business, where she is also an adjunct professor. Ms. Keller was named one of FierceBiotech 10 Top Women in Biotech in 2012. since 2017.
| Age | 57 |
| Tenure | 7 years |
| Address | 530 Herman O. West Drive, Exton, PA, United States, 19341-1147 |
| Phone | 610 594 2900 |
| Web | https://www.westpharma.com |
West Pharmaceutical Management Efficiency
The company has Return on Asset of 0.1 % which means that on every $100 spent on assets, it made $0.1 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1778 %, implying that it generated $0.1778 on every 100 dollars invested. West Pharmaceutical's management efficiency ratios could be used to measure how well West Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.17 in 2024. Return On Capital Employed is likely to gain to 0.22 in 2024. At this time, West Pharmaceutical's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 4 B in 2024, despite the fact that Change To Liabilities is likely to grow to (3.1 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Mahoney | Baxter International | 56 | |
| Gretchen Haggerty | Teleflex Incorporated | 65 | |
| Robert Abernathy | Haemonetics | 66 | |
| George Babich | Teleflex Incorporated | 69 | |
| Ronald Taylor | ResMed Inc | 72 | |
| Gary Petersmeyer | The Cooper Companies, | 73 | |
| Harjit Gill | ResMed Inc | 55 | |
| Carol Burt | ResMed Inc | 62 | |
| Jan Witte | ResMed Inc | 56 | |
| Amy Wendell | Baxter International | 60 | |
| Rebecca Rimel | Becton Dickinson and | 69 | |
| Charles Dockendorff | Haemonetics | 66 | |
| David Wilkes | Baxter International | 64 | |
| Catherine Burzik | Haemonetics | 70 | |
| Nancy Schlichting | Baxter International | 66 | |
| Colleen Jay | The Cooper Companies, | 58 | |
| Kim Duncan | The Cooper Companies, | N/A | |
| Thomas Stallkamp | Baxter International | 73 | |
| Catherine Burzik | Becton Dickinson and | 70 | |
| John Forsyth | Baxter International | 73 | |
| Claire Pomeroy | Becton Dickinson and | 65 | |
Management Performance
West Pharmaceutical Leadership Team
Elected by the shareholders, the West Pharmaceutical's board of directors comprises two types of representatives: West Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of West. The board's role is to monitor West Pharmaceutical's management team and ensure that shareholders' interests are well served. West Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, West Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Buthman, Independent Director | ||
| Deborah Tanner, Independent Director | ||
| Bernard Birkett, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer | ||
| Eric Green, President, Chief Executive Officer, Director | ||
| John CFA, Head Relations | ||
| Rudy Poussot, Senior Development | ||
| Dr CFA, Vice Relations | ||
| William Feehery, Independent Director | ||
| Robert Friel, Independent Director | ||
| Richard Luzzi, VP HR | ||
| Myla LaiGoldman, Independent Director | ||
| Paula Johnson, Independent Director | ||
| Douglas Michels, Independent Director | ||
| Michele Polinsky, Vice Communications | ||
| Kimberly MacKay, Senior Vice President General Counsel, Corporate Secretary | ||
| Paolo Pucci, Independent Director | ||
| Annette Favorite, Chief Human Resource Officer, Senior Vice President | ||
| Patrick Zenner, Independent Chairman of the Board | ||
| Thomas Hofmann, Independent Director | ||
| Silji Abraham, Senior Vice President and Chief Digital and Transformation Officer | ||
| David Montecalvo, Senior Vice President, Chief Operating and Supply Chain Officer | ||
| Christopher Ryan, Senior Vice President of Commercial Products and Emerging Markets | ||
| Quintin Lai, Vice President - Corporate Development, Strategy and Investor Relations | ||
| Molly Joseph, Director | ||
| George Miller, Senior Vice President General Counsel, Corporate Secretary | ||
| Cindy ReissClark, Senior Vice President of Global Market Units and Commercial Solutions | ||
| Chad Winters, Chief Accounting Officer, Principal Accounting Officer, Vice President, Corporate Controller | ||
| Robert Segura, VP Devel | ||
| Eric Resnick, Chief Technology Officer, Vice President |
West Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is West Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 22.74 B | ||||
| Shares Outstanding | 72.42 M | ||||
| Shares Owned By Insiders | 0.58 % | ||||
| Shares Owned By Institutions | 96.69 % | ||||
| Number Of Shares Shorted | 1.43 M | ||||
| Price To Earning | 40.71 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for West Stock Analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.